Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Azuma

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Journal of Cardiac Surgery|September 1, 1988
Five-year follow-up of Hancock pericardial valves: management of premature failureH Scully, B Goldman, J Fulop, et al.
Archives of Biochemistry and Biophysics|August 10, 2000
The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6T Fukuda, Y Nishida, S Imaoka, et al.
International Journal of Cardiology|January 1, 1982
Taurine for treatment of congestive heart failureJ Azuma, H Hasegawa, A Sawamura, et al.
European Journal of Pharmacology|June 19, 1981
Trapidil stimulation of slow Ca2+ current in cardiac muscleJ Azuma, A Sawamura, H Harada, et al.
Japanese Journal of Pharmacology|February 7, 2002
Protective effect of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cellsX Ouyang, K Takahashi, K Komatsu, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1991
Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicityJ Azuma, T Kurimoto, S Tsuji, et al.
Life Sciences|November 4, 1985
Taurine's possible protective role in age-dependent response to calcium paradoxK Takihara, J Azuma, N Awata, et al.
Biochemical and Biophysical Research Communications|August 27, 1999
Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liverA Sumida, K Kinoshita, T Fukuda, et al.
The Pharmacogenomics Journal|March 23, 2002
CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitroT Hanatani, T Fukuda, M Ikeda, et al.
Translational Psychiatry|February 25, 2015
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTsM Kato, A Serretti, S Nonen, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Journal of Cardiac Surgery|September 1, 1988
Five-year follow-up of Hancock pericardial valves: management of premature failureH Scully, B Goldman, J Fulop, et al.
Archives of Biochemistry and Biophysics|August 10, 2000
The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6T Fukuda, Y Nishida, S Imaoka, et al.
International Journal of Cardiology|January 1, 1982
Taurine for treatment of congestive heart failureJ Azuma, H Hasegawa, A Sawamura, et al.
European Journal of Pharmacology|June 19, 1981
Trapidil stimulation of slow Ca2+ current in cardiac muscleJ Azuma, A Sawamura, H Harada, et al.
Japanese Journal of Pharmacology|February 7, 2002
Protective effect of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cellsX Ouyang, K Takahashi, K Komatsu, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1991
Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicityJ Azuma, T Kurimoto, S Tsuji, et al.
Life Sciences|November 4, 1985
Taurine's possible protective role in age-dependent response to calcium paradoxK Takihara, J Azuma, N Awata, et al.
Biochemical and Biophysical Research Communications|August 27, 1999
Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liverA Sumida, K Kinoshita, T Fukuda, et al.
The Pharmacogenomics Journal|March 23, 2002
CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitroT Hanatani, T Fukuda, M Ikeda, et al.
Translational Psychiatry|February 25, 2015
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTsM Kato, A Serretti, S Nonen, et al.
Pageof 14